- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Clarifying meaningful use stage 2 now that CMS has announced its final rule
Dermatologists and other eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) can now review the upcoming meaningful use stage 2 requirements, now that the Centers for Medicaid and Medicare Services has announced its "final rule" for attestation of meaningful use (MU) stage 2.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Tips and Tricks for Successful Practice Management with Leon Kircik, MD
Best Tips for Building and Marketing a Dermatologic Practice
The Business of Skin Care
Pain-Free Dermatology: Minimizing Discomfort
How to Navigate Volatile Markets
An In-depth Guide to a Medical Practice's Legal and Tax Options
Experts Discuss How to Know if Your Practice’s Retirement Plan at Risk
Navigating the Savings Potential of Cash Balance Plans
How to Make Your Practice Stand Out
Health Care Impacts on Gender and Sexual Minority Patients
Related Content
Published: March 8th 2025 | Updated: March 8th 2025
